Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022

Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
CANNANNEW REPORT

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Company’s Investor Relations website and embedded into the live webcast. Conference Call and Webcast Information – Live Date: Thursday, May 12, 2022, at 4:30 p.m. Eastern Time   Dial in: 844-887-9402 412-317-6798 (international)   Hosts: Dr. James A. Hayward, chairman, president, and CEO Beth Jantzen, chief financial officer   Webcast: https://services.choruscall.com/mediaframe/webcast.html?webcastid=oxAfF9iN Conference Call and Webcast Information – Replay A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call. Dial in: 877-344-7529 412-317-0088 (international) Access Code: 8190790   Webcast: https://services.choruscall.com/mediaframe/webcast.html?webcastid=oxAfF9iN   Availability: Telephonic replay: until Thursday, May 19, 2022; webcast replay: 1 year About Applied DNA Sciences Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale cell-free production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR T therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting…

Excerpt only …
READ MORE BELOW
Source : Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.